Fluzone Articles
MedImmune a step closer to FluMist approval?
15 July 2002
MedImmune posts major losses
6 May 2002
PowderJect moves into the black as vaccine sales increase
16 November 2001
FDA responds to Aviron after FluMist review
5 September 2001
Stock Commentary - New York
2 August 2001
PowderJect to extend production of Fluvirin vaccine
2 August 2001
Stock Commentary - New York
1 August 2001
BB Biotech posts hefty loss in first-half 2001
31 July 2001
Aviron's nasal flu vaccine turned down by FDA panel
30 July 2001
New AHP CEO reviews growth strategy
25 May 2001
Boost for Aviron as FluMist clears hurdle
2 January 2001
Vaccines acquisition set to drive near-term growth at PowderJect
12 December 2000
Aviron files BLA for FluMist
3 November 2000
Aviron signs two UK deals, with PowderJect and Celltech
12 October 2000
PowderJect to acquire Medeva vaccines business for L55 million
7 September 2000
Aviron raises $8 million
15 June 2000
Aviron share sale
17 April 2000
Weston looking to raise L50 million
28 March 2000
Aviron to file for FluMist approval in fourth-quarter
16 March 2000
Agouron boosted on drug for common cold
16 December 1999
Stock Commentary New York
18 November 1999
Aviron delays filing of FluMist in USA again
16 November 1999
Fast-track approval for GW's Lotronex (update)
31 August 1999
GW's Relenza slated for October launch
26 August 1999
Currency impact lifts SmithKline Beecham
20 April 1999
Medeva confident about its future
12 February 1999
Wyeth signs FluMist deal with Aviron
14 January 1999
Aviron's FluMist Phase III Data
8 December 1998
BioChem's Flu Vaccine
29 October 1998
New Drugs, Vaccine Shift Balance In War Against Flu
30 September 1998
Setback For Aviron With FluMist
10 September 1998
SKB 1998 Fluarix Now Available
3 September 1998
Aviron's FluMist "Non-Filable," Says FDA
2 September 1998
Phase III Data Support FluMist Efficacy
6 August 1998
Aviron Signs First FluMist Licensing Deal
25 June 1998
Aviron's FluMist Has 93% Efficacy
14 May 1998
UK's Medeva Redefining Product Portfolio
18 February 1998
SB Launches Fluarix In UK
11 September 1997
Strong Growth In 1996 As Medeva Builds In the USA
24 February 1997
Medeva Takes On Single Isomer Methylphenidate
27 January 1997
SmithKline Beecham: A Leader In Spanish Market
19 August 1996
Medeva Shows Its Strength After Failed Merger Talks
26 February 1996
Intranasal flu vaccine from Aviron
20 November 1995
SmithKline Beecham Unveils Power Pipeline
9 October 1995
Medeva "Not For Sale" But Is On Track For Growth
24 July 1995
Medeva Acquires US Vaccines
10 July 1995
Medeva's 1994 Results Crown Five Years Of Growth
27 March 1995
Excellent Results For Medeva In 1994
20 March 1995
MEDEVA'S PROFITS AHEAD OF EXPECTATIONS
21 March 1994
MEDEVA'S FLUVIRIN
5 April 1993
MEDEVA MAKES FIRST EURO ACQUISITION
8 February 1993
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
